1. 1 Table S1. Human peptide sequences with homology to E6 29-38 *. Protein NameSequenceGene exocyst complex component 2TIQDLILDLREXOC2 BAG family molecular chaperone regulator 5 isoform b**AVQEIIEDCMBAG5 aconitate hydratase, mitochondrial precursorIIHQIILENYACO2 PREDICTED: receptor-type tyrosine-protein phosphatase gamma isoform X2IIHDFILEATPTPRGX2 receptor-type tyrosine-protein phosphatase gammaFIHDALLEAIPTPRG diencephalon/mesencephalon homeobox protein 1 isoform bTFQDIILEARDMBX1 BTB/POZ domain-containing protein 16GEADVILECLBTBD16 receptor-type tyrosine-protein phosphatase U isoform 4 precursorFIHDAILEACPTPRU protein prune homologLHGTIILDCVPRUNE heat shock cognate 71 kDa protein isoform 2QIHDIVLVGGHSPA8 heat shock 70 kDa protein 1-likeKIHDIVLVGGHSPA1L laminin subunit gamma-2 isoform b precursorSAHDVILEGALAMC2 LIM domain only protein 7 isoform 2VERDIILQCRLMO7 retrotransposon gag domain-containing protein 4DLDELILECVRGAG4 nucleoside diphosphate kinase homolog 5EIQDIILRSGNME5 BAG family molecular chaperone regulator 5 isoform b**GIQDIILRLTBAG5 *Peptides sharing at least six amino acids or five amino acids plus a conservative substitution with E6 29-38 (TIHDIILECV). Black font indicates shared positions (including conservative substitutions). **Different peptides from the same protein.

2. Figure S1. Functional avidity and tumor recognition assays testing genetically engineered (retrovirally transduced) human T cells expressing TCRs raised by peptide vaccination of HLA-A*02:01 transgenic mice. IFN-  production as determined by ELISA following overnight coculture of T cells genetically engineered with (A) a TCR targeting E6 29-38 with the targets indicated on the x-axis or (B) either of two TCRs targeting E7 11-19. The clonotype of the engineered TCRs expressed by the effector cells is shown in the figure legends. NY-ESO-1 157-165 is a HLA-A*02:01 restricted peptide used as a negative control. In panel A, targets included 293-A2 cell lines transfected with a plasmid encoding full length E6 or E7. Effector cells from panel B did not show recognition of transfected targets in a separate experiment (although positive controls were lacking since effector cells that could recognize these targets had not been described).

3. Figure S2. Testing of HPV+ cell lines for HLA-A*02:01-restricted recognition by T cells. (A) To determine if HPV-16+ cell lines expressed sufficient HLA-A*02:01 for recognition by E7 11-19 -specific T cells, SCC90, CaSki, and 624-E7 lines were pulsed with E7 11-19 peptide (or the controls shown in the figure legend) and cocultured overnight with human T cells transduced to express the TRBV16 TCR (E7 11-19 -specific) shown in Figure S1B. IFN-  production as determined by ELISA following overnight coculture is shown. (B) Chimeric HPV-16-MART1 cell lines were generated by transduction of SCC90 and CaSki with a retrovirus encoding MART1. Following antibiotic selection, real-time RT-PCR was performed to determine relative MLANA (gene encoding MART1) expression. SCC90- MART1 and CaSski-MART1 are the MART1-transduced cells lines. 624 was a positive control melanoma cell line. (C) IFN-  production as determined by ELISA following overnight coculture of human T cells retrovirally transduced to express either the high (mF5) or low (F4) avidity TCRs targeting an HLA-A*02:01-restricted epitope of MART1.